Physician profile
Jason Owyang
NPI 1972928059
$1,486.02
in general payments reported to CMS, 2019-2025
20 companies · $914 in 2025
The $914 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.90 · 2023: $153 · 2024: $375 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $220.49 | 2024-2025 | (5050) Ext Holter, Mcot, (5044) Mcot |
| Lilly USA, LLC | $198.00 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $192.16 | 2024-2025 | |
| Edwards Lifesciences Corporation | $109.05 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.98 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $99.23 | 2022-2023 | |
| Glaxosmithkline, LLC. | $94.82 | 2025 | Shingrix, Bexsero |
| Novo Nordisk INC | $91.09 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $71.20 | 2025 | Rexulti |
| Impulse Dynamics (USA) INC. | $58.66 | 2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $46.07 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $38.22 | 2023-2024 | Verquvo, Lagevrio, Belsomra |
| Boston Scientific Corporation | $27.65 | 2025 | Bodyguardian |
| Exact Sciences Corporation | $23.71 | 2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $22.66 | 2025 | Heplisav-B |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.66 | 2025 | Xifaxan |
| Irhythm Technologies, INC. | $18.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.24 | 2025 | Wainua |
| Janssen Pharmaceuticals, INC | $17.78 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $16.40 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Owyang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.